Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 793-798

  Chung, Young Sik ^a   Miyatake, Shin Ichi ^a   Miyamoto, Akiko ^a   Miyamoto, Yoshiharu ^a   Dohi, Takehiko ^a   Tanigawa, Nobuhiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

G92A; Gene therapy; hrR3; Malignant liver tumor; Recombinant herpes simplex virus

Indexed keywords

CANCER VACCINE; RECOMBINANT DNA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL STRAIN HT29; CERCOPITHECUS; DEFECTIVE VIRUS; DRUG SCREENING; FEMALE; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOLOGY; LIVER; LIVER TUMOR; MORTALITY; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE; TUMOR CELL LINE; VERO CELL; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DEFECTIVE VIRUSES; DNA, RECOMBINANT; FEMALE; GENETIC VECTORS; HT29 CELLS; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; SIMPLEXVIRUS; SURVIVAL RATE; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744719735     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.793     Document Type: Article

References (31)

1. Vile RG, Diaz RM, Miller N, et al: Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214: 307-313, 1995.
2. Miyatake S, Iyer A, Martuza RL, et al: Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 71: 5124-5132, 1997.
3. Miyatake SI, Tani S, Feigenbaum F, et al: Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 6: 564-572, 1999.
4. Goldstein DJ and Weller SK: Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166: 41-51, 1988.
5. Carroll NM, Chiocca EA, Takahashi K, et al: Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224: 323-330, 1996. (Pubitemid 26307474)
6. Kramm CM, Chase M, Herrlinger U, et al: Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8: 2057-2068, 1997.
7. Kasuya H, Nishiyama Y, Nomoto S, et al: Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 72: 136-141, 1999.
8. Mineta T, Rabkin SD, Yazaki T, et al: Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943, 1995.
9. Yazaki T, Manz HJ, Rabkin SD, et al: Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55: 4752-4756, 1995.
10. Toda M, Martuza RL, Kojima H, et al: In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160: 4457-4464, 1998.
11. Sundaresan P, Hunter WD, Martuza RL, et al: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 74: 3832-3841, 2000.
12. Yoon SS, Carroll NM, Chiocca EA, et al: Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 228: 366-374, 1998.
13. Kucharczuk JC, Randazzo B, Chang MY, et al: Use of a 'replication- restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57: 466-471, 1997.
14. Coukos G, Makrigiannakis A, Kang EH, et al: Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 5: 1523-1537, 1999.
15. Varghese S and Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9: 967-978, 2002. (Pubitemid 35462560)
16. Coukos G, Makrigiannakis A, Kang EH, et al: Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 6: 3342-3353, 2000.
17. Bennett JJ, Delman KA, Burt BM, et al: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 9: 935-945, 2002.
18. Markert JM, Medlock MD, Rabkin SD, et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874, 2000.
19. Kasuya H, Takeda S, Nomoto S, et al: The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 12: 725-736, 2005.
20. Kooby DA, Carew JF, Halterman MW, et al: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13: 1325-1334, 1999.
21. Yoon SS, Nakamura H, Carroll NM, et al: An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 14: 301-311, 2000.
22. Bennett JJ, Kooby DA, Delman K, et al: Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 78: 166-174, 2000.
23. Bennett JJ, Malhotra S, Wong RJ, et al: Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 233: 819-826, 2001.
24. Bennett JJ, Tjuvajev J, Johnson P, et al: Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med 7: 859-863, 2001. (Pubitemid 32691643)
25. Iizuka Y, Suzuki A, Kawakami Y, et al: Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12. J Immunother 27: 92-98, 2004.
26. Stanziale SF, Petrowsky H, Adusumilli PS, et al: Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 10: 3225-3232, 2004.
27. Boviatsis EJ, Chase M, Wei MX, et al: Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther 5: 183-191, 1994.
28. Boviatsis EJ, Scharf JM, Chase M, et al: Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1: 323-331, 1994. (Pubitemid 124000561)
29. Miyatake S: Gene therapy using tissue-specific replication competent HSV. Hum Cell 15: 130-137, 2002.
30. Krisky DM, Marconi PC, Oligino TJ, et al: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 5: 1517-1530, 1998.
31. Krisky DM, Wolfe D, Goins WF, et al: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 5: 1593-1603, 1998.